Company intelligence / Profile preview

SATOR Therapeutics

Cleveland, Ohio, United Statessatortx.com ↗

Ownership: Private
Employees: ~11
Development stage: Other

Overview

SATOR Therapeutics has developed a portfolio of nearly 30 proprietary oncolytic viruses. Their lead candidate, STR-0011, is being advanced for mesothelioma and is currently at the preclinical stage. Additional candidates targeting mesothelioma and glioblastoma are in earlier stages. The company also pursues companion diagnostics and novel delivery approaches but has not yet reported clinical results.

Therapeutic areas: Oncology
Modalities: Oncolytic virus therapyBiologic (as oncolytic viruses are biologic agents)
Industry: Biotech

Drug pipeline

3 assets

STR-0011

Preclinical

2 more assets in the full pipeline.

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on SATOR Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SATOR Therapeutics.